Table 2 Comparison of the nonrecurrent and recurrent patient groups

Sex [male (%)]

15 (71.4%)

2 (33.3%)

0.15

Age (years)

76 (63–83)

79 (66–83)

0.52

Length of stay

15 (10–27)

14 (9–36)

0.82

TG18 grade

 II

9 (42.9%)

3 (50.0%)

1

 III

12 (57.1%)

3 (50.0%)

aCCI

4 (3–5)

5 (4–5)

0.13

Preoperative body temperature (℃)

38.0 (37.2–39.2)

37.5 (36.6–38.5)

0.15

Initial laboratory values

 Platelets (× 10⁹ L)

172.0 (114.0–294.0)

163.50 (101.75–284.25)

0.77

 White blood cells (× 10⁹ L)

11.4 (8.6–17.2)

6.2 (4.2–9.7)

0.031

 Neutrophil granulocytes (%)

86.1 (75.5–93.0)

74.6 (68.0–82.3)

0.047

 ALT (U/L)

39.0 (24.5–92.5)

27.0 (21.7–91.8)

0.56

STB (μmol/L)

20.0 (13.6–33.9)

17.0 (7.9–23.8)

0.24

 CB (μmol/L)

1.4 (0–10.2)

1.9 (0–5.4)

0.62

 UCB (μmol/L)

9.4 (3.7–13.8)

6.2 (3.5–18.5)

0.86

CHD or CHF

3 (14.3%)

4 (66.7%)

0.024

26.50 (1.21–582.06) 0.038

Diabetes

3 (14.3%)

3 (50.0%)

0.10

Cerebrovascular disease

4 (19.0%)

3 (50%)

0.29

Malignancy

4 (19.0%)

2 (33.3%)

0.59

Clinical effectiveness

16 (76.2%)

5 (83.3%)

1